The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder - A systematic review

Research in Developmental Disabilities

Volumn 35, Issue 3, 2014, Pages 711-725

  Deb, Shoumitro ^a   Farmah, Baldeep K ^b   Arshad, Ebrahim ^c   Deb, Tanya ^a   Roy, Meera ^d   Unwin, Gemma L ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Health Education Kent   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Birmingham Dental School   (United Kingdom)

Author keywords

Aggression; Aripiprazole; ASD; Developmental disabilities; Intellectual disabilities; Problem behaviour; Self injurious behaviour

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; NEUROLEPTIC AGENT; PROLACTIN; VALPROIC ACID;

AGGRESSION; AKATHISIA; AUTISM; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CONSTIPATION; COUGHING; DAYTIME SOMNOLENCE; DEVELOPMENTAL DISORDER; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; INTELLECTUAL IMPAIRMENT; NAUSEA; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; QT PROLONGATION; QUALITY OF LIFE; RASH; RETROSPECTIVE STUDY; REVIEW; SEDATION; SOMNOLENCE; SYSTEMATIC REVIEW; TREMOR; VOMITING;

AGGRESSION; ARIPIPRAZOLE; ASD; DEVELOPMENTAL DISABILITIES; INTELLECTUAL DISABILITIES; PROBLEM BEHAVIOUR; SELF-INJURIOUS BEHAVIOUR;

AGGRESSION; ANTIPSYCHOTIC AGENTS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DEVELOPMENTAL DISABILITIES; HUMANS; INTELLECTUAL DISABILITY; MENTAL DISORDERS; PIPERAZINES; QUINOLONES; SELF-INJURIOUS BEHAVIOR; TREATMENT OUTCOME;

EID: 84896392374     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2013.12.004     Document Type: Review

References (45)

1. Aman M.G., Burrow W.H., Wolford P.L. The aberrant behavior checklist-community: Factor validity and effect of subject variables for adults in group homes. American Journal of Mental Retardation 1995, 100(3):283-292.
2. Challenging behaviour: A unified approach (Clinical and service guidelines for supporting people with learning disabilities who are at risk of receiving abusive or restrictive practices) 2007, The Royal College of Psychiatrists, The British Psychological Society and The Royal College of Speech and Language Therapists, London, UK, (College Report CR 144, June, 2007). R. Banks, A. Bush, P. Baker, J. Bradshaw, P. Carpenter, S. Deb (Eds.).
3. Barnes T.R. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989, 154:672-676.
4. Basgul S.S., Uneri O. Use of aripiprazole in children and adolescents: Case reports. Child and Adolescent Psychiatry 2011, 20(S1):S7-S223. P21-01.
5. Berney T., Deb S. Epilepsy in learning disability. Oxford textbook of epilepsy and epileptic seizures: Oxford textbooks in clinical neurology 2012, 195-199. Oxford University Press, Oxford, UK. S. Shorvon, R. Guerrini, M. Cook, S. Lahtoo (Eds.).
6. Deb S. Epilepsy in people with mental retardation. Handbook of mental retardation and developmental disabilities 2007, 81-96. Kluwer Academic Publishers, New York, USA. J.W. Jacobson, J.A. Mulick (Eds.).
7. Deb S. Psychopharmacology. Handbook of psychopathology in intellectual disability: Research, practice, and policy, autism and child psychopathology series 2013, 307-324. Springer Science+Business Media, New York, USA, (Series Editor: Johnny L. Matson; book chapter 19). E. Tsakanikos, J. McCarthy (Eds.).
8. Deb S., Clarke D., Unwin G. Using medication to manage behaviour problems among adults with a learning disability: Quick reference guide (QRG) 2006, University of Birmingham, MENCAP, The Royal College of Psychiatrists, London, UK. http://www.ld-medication.bham.ac.uk/.
9. Deb S., Fraser W.I. The use of psychotropic medication in people with learning disability: Towards rational prescribing. Human Psychopharmacology 1994, 9:259-272.
10. Deb S., Kwok H., Bertelli M., Salvador-Carulla L., Bradley E., Torr J., et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry 2009, 8(3):181-186.
11. Deb S., Sohanpal S.K., Soni R., Unwin G., LenÔtre L. The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. Journal of Intellectual Disability Research 2007, 51(10):766-777.
12. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology and Community Health 1998, 52(6):377-438.
13. Dratcu L., McKay G., Singaravelu V., Krishnamurthy V. Aripiprazole treatment of Asperger's syndrome in the acute psychiatric setting: Case report. Neuropsychiatric Disease and Treatment 2007, 3(1):173-176.
14. Einfeld S.L. Systematic management approach to pharmacotherapy for people with learning disabilities. Advances in Psychiatric Treatment 2004, 7:43-49.
15. Erickson C.A., Stigler K.A., Wink L.K., Mullett J.E., Kohn A., Posey D.J., et al. A prospective open-label study of aripiprazole in fragile X syndrome. Journal of Psychopharmacology 2011, 216(1):85-90.
16. Fung L.K., Chahal L., Libove R.A., Bivas R., Hardan A.Y. A retrospective review of the effectiveness of aripiprazole in the treatment of sensory abnormalities in autism. Journal of Child and Adolescent Psychopharmacology 2012, 22(3):245-248.
17. Guy W. ECDEU assessment manual for psychopharmacology 1976, 217-222. CDHEW; No: 76-338, US Department of Health, Education and Welfare, Rockville, MD.
18. Guy W. Abnormal involuntary movement scale (AIMS). ECDEU assessment manual for psychopharmacology 1976, 534-537. US Department of Health, Education and Welfare publication (ADM) 76-338, National Institute of Mental Health, Rockville, MD.
19. Hall S., Deb S. A qualitative study on the knowledge and views that people with learning disabilities and their carers have of psychotropic medication prescribed for behaviour problems. Advances in Mental Health and Learning Disabilities 2008, 2(1):29-37.
20. Han M., Huang X-F., Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: Implications for long-term drug efficacy and low extrapyramidal side-effects. International Journal of Neuropsychopharmacology 2009, 12(7):941-952.
21. Hellings J.A., Boehm D., Yeh H.W., Butler M.G., Schroeder S.R. Long-term aripiprazole in youth with developmental disabilities including autism. Journal of Mental Health Research in Intellectual Disabilities 2011, 4(1):40-52.
22. Hemmings C., Deb S., Chaplin E., Hardy S., Mukherjee R. Research for people with intellectual disabilities and mental health problems: A view from the UK. Journal of Mental Health Research in Intellectual Disability 2013, 6(2):127-158.
23. Huang S.C., Tsai S.J., Yang H.J. Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder. Chang Gung Medical Journal 2010, 33(2):211-215.
24. Ishitobi M., Hiratani M., Kosaka H., Takahashi T., Mizuno T., Asano M., et al. Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2012, 37(1):128-131.
25. Jordan I., Robertson D., Catani M., Craig M., Murphy D. Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder. Psychopharmacology 2012, 223(3):357-360.
26. Kültür S.E.C., Tiryaki A., Tasgin E. Aripiprazole for maladaptive behavior in mental retardation: Case reports. Bulletin in Clinical Psychopharmacology 2009, 19(3):294-297.
27. Marcus R.N., Owen R., Kamen L., Manos G., McQuade R.D., Carson W.H., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of American Academy of Child and Adolescent Psychiatry 2009, 48(11):1110-1119.
28. Marcus R.N., Owen R., Manos G., Mankoski R., Kamen L., McQuade R.D., et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: Results from a 52-week, open-label study. Journal of Child and Adolescent Psychopharmacology 2011, 21(3):229-236.
29. Marcus R.N., Owen R., Manos G., Mankoski R., Kamen L., McQuade R.D., et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. Journal of Clinical Psychiatry 2011, 72(9):1270-1276.
30. Masi G., Cosenza A., Millepiedi S., Muratori F., Pari C., Salvadori F. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: A retrospective study. CNS Drugs 2009, 23(6):511-521.
31. Oliver-Africano P.C., Dickens S., Ahmed Z., Bouras N., Cooray S., Deb S., et al. Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. Journal of Intellectual Disability Research 2010, 54(1):17-25.
32. Owen R., Sikich L., Marcus R.N., Corey-Lisle P., Manos G., McQuade R.D., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Journal of American Academy of Child and Adolescent Psychiatry 2009, 124(6):1533-1540.
33. Pardini M., Guida S., Gialloreti L.E. Aripiprazole treatment for coprophagia in autistic disorder. Journal of Neuropsychiatry 2010, 22(4):451-s.e33.
34. Reiss S., Aman M.G. Psychotropic medication and development disabilities: The international consensus handbook 1998, Ohio State University, Columbus, OH.
35. Scahill L., Riddle M.A., McSwiggin-Hardin M., Ort S.I., King R.A., Goodman W.K., et al. Children's yale-brown obsessive compulsive scale: Reliability and validity. Journal of American Academy of Child and Adolescent Psychiatry 1997, 36(6):844-852.
36. Shashtri M., Alla L., Sabaratnam M. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: A case series. Journal of Psychopharmacology 2006, 20(6):863-867.
37. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplement 1970, 212:11-19.
38. Staller J.A. Aripiprazole in an adult with Asperger disorder. Annals of Pharmacotherapy 2003, 37(11):1628-1631.
39. Stigler K.A., Diener J.T., Kohn A.E., Li L., Ericson C.A., Posey D.J., et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: A 14-week, prospective, open-label study. Journal of Child and Adolescent Psychopharmacology 2009, 19(3):265-274.
40. Stigler K.A., Mcdougle C.J., Scahill L., Aman M.G., Eugene A.L., Johnson C., et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Effectiveness and tolerability of aripiprazole in risperidone nonresponders. Neuropsychopharmacology 2011, 36:S228.
41. Stigler K.A., Posey D.J., McDougle C.J. Aripiprazole for maladaptive behavior in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 2004, 14(3):455-463.
42. Unwin G., Deb S. Psychotropic medication easy read information leaflets 2007, University of Birmingham, UK. http://www.ld-medication.bham.ac.uk/.
43. Unwin G.L., Deb S. The use of medication to manage problem behaviours in adults with a learning disability: A national guideline. Advances in Mental Health in Intellectual Disabilities 2010, 4(3):4-11.
44. Unwin G.L., Deb S. Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review. Research in Developmental Disabilities 2011, 32:2121-2133.
45. Valicenti-McDermott M.R., Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. Journal of Child and Adolescent Psychopharmacology 2006, 16(5):549-560.